Myelodysplastic neoplasms/syndromes (MDS) research hub

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

This study is looking at a new medicine, Elritercept, for people with a type of blood condition called myelodysplastic syndromes (MDS). It compares Elritercept to a standard treatment, Epoetin Alfa, to see if it can help reduce the need for blood transfusions.